You are here

Clinical Trials

The Department of Surgery doesn’t just excel in the operating room. Through our extensive and innovative research programs, we are also focused on the development of new techniques and therapies that promote better outcomes and improve the quality of life for patients following surgery. 

As part of that goal, the department’s surgeons are involved in groundbreaking clinical trials. In addition to their research value, clinical trials may also give patients access to new treatments that are not available anywhere else.

Learn more about our current clinical trials below or visit the Joint Clinical Trials Office at Weill Cornell Medicine and NewYork-Presbyterian.

This clinical trial is to evaluate an experimental (investigational) study drug in men or women who have been diagnosed with Primary Biliary Cholangitis (PBC). EDP-305 is considered to be experimental meaning it is not approved by the U.S.

Key Inclusion / Exclusion Criteria:
  • Men and women who are 18 years of age and older. 
  • Individuals with been diagnosed with Primary Biliary Cholangitis (PBC). 
  • Detailed eligibility reviewed when contacting the study team. 

Exposure to radiation can impact immune cells that are present in the blood, such as lymphocytes. It is hypothesized that larger radiation fields and/or longer courses of radiation, result in greater decrease in immune cells.

Key Inclusion / Exclusion Criteria:

   1. Age ≥ 18
   2. For cohort 1a and b: Prostate cancer subjects undergoing 9 week radiation
   a. Biopsy-proven diagnosis of prostate adenocarcinoma
   3. For cohort 2a : Breast cancer subjects undergoing standard fractionation RT of 5 weeks
   a. Biopsy-proven diagnosis of invasive breast cancer, s/p breast surgery to negative margins, and requiring adjuvant breast and nodal RT
   4. For cohort 2b: Breast cancer subjects undergoing PBI
   a. Post-menopausal women defined as either 1) at least 2 years without menstrual period or 2) or patients older than 50 with serological evidence of post-menopausal status or 3) hysterectomized patients of any age with FSH confirmation of post-menopausal status.
   b. Post-segmental mastectomy with negative margins
   c. Clinically N0 or pN0 or sentinel node negative

Additional eligibility criteria reviewed when you contact the study team. 

This study is for men and women who are 65 years or older with cancer and informal caregivers of people 65 years or older with cancer.

Key Inclusion / Exclusion Criteria:

Open to men and women age 65 years or older 
Diagnosis of cancer
Experiencing elevated anxiety

Open to men and women 
Providing informal (unpaid) care to a person age 65 years or older with cancer
Experiencing elevated anxiety

The purpose of this study is to evaluate the use of a novel exercise treadmill test (ETT) electrocardiogram (ECG) indices as biomarkers in the assessment of Atherosclerotic Coronary Vascular Disease (ASCVD) (a Coronary Artery Disease or CAD) and to determine how the indices are affected by fatty

Key Inclusion / Exclusion Criteria:
  • History of stable coronary artery disease as defined by the presence of greater or equal to one of the following:
    • Stable angina (chest pain) that is medically treated (minimum 3 month history)
    • History of exercise treadmill test and/or other imaging suggesting ischemic coronary disease which has required ongoing medical treatment
    • History of coronary angiography with or without coronary intervention/PTCA with greater or equal to 1 vessel with greater or equal to 50% stenosis at the end of the procedure (or after any intervention)

The purpose of this study is to identify the incidence, risk factors and biomarkers for subclinical chronic kidney damage kidney transplant patients recipients managed with early a steroid withdrawal protocol.

This study is being done to collect blood samples from patients (men and women) diagnosed with liver disease, cirrhosis or liver or bile duct cancer.

Key Inclusion / Exclusion Criteria:

Men and women who are 18 years of age and older.

- Patients who have been diagnosed with liver disease, cirrhosis or liver or bile duct cancer.

- Detailed eligibility reviewed when the individual contacts the study team. 

This clinical trial is for men and women newly diagnosed with glioblastoma or anaplastic gliomas. There is a great need for new treatment options for patients diagnosed with malignant brain tumors.

Key Inclusion / Exclusion Criteria:
  • Open to men and women who are 18 and older 
  • Diagnosed with glioblastoma or anaplastic glioma 
  • Participants must be newly diagnosed
  • Detailed eligibility will be reviewed when you contact the study team 


The purpose of this study is to determine whether etrolizumab is a safe and effective treatment for patients with moderate to severe Crohn’s Disease. 

Key Inclusion / Exclusion Criteria:

- 18-80 years of age (inclusive) 

- Moderately to severely active Crohn's disease as determined by the Crohn's Disease

- Activity Index (CDAI), patient reported outcomes and endoscopically defined disease activity in the ileum and/or colon 

- Intolerance, loss of response or failure to respond to corticosteroids (CS) or, immunosuppressants (IS), or TNF inhibitors within the previous 5 years 

- Use of effective contraception as defined by the protocol 
Exclusion Criteria: 
- A history of, or current conditions affecting the digestive tract, such as ulcerative colitis, indeterminant colitis, fistulizing disease, abdominal or perianal abscess, adenomatous colonic polyps not excised, colonic mucosal dysplasia, and short bowel syndrome 

- Planned surgery for CD Ileostomy or colostomy 

- Has received non-permitted inflammatory bowel disease (IBD) therapies (including natalizumab, vedolizumab, and efilizumab, as stated in the protocol) 

- Chronic hepatitis B or C infection, HIV, active or latent tuberculosis (patients with prior history of BCG vaccination must pass protocol-defined screening criteria) 

The purpose of this study is to learn more about a patient’s transplant and related complications. We will develop tests for assessing the status of the kidney transplant, as well as any potential complications.

This study will follow patients seen in the in/outpatient setting at Weill Cornell Medical College with current or past diagnosis of heart failure (HF) and pulmonary hypertension (PH). The study has three specific aims:

Key Inclusion / Exclusion Criteria:

Inclusion criteria:

  • All inpatients and outpatients at Weill Cornell Medical Center whose principal or consulting attending physician is Dr. Sobol or Dr. Horn (co-investigator on this study) who have been diagnosed with HF (either with preserved or depressed ejection fraction) and/or pulmonary hypertension will be eligible to participate.

Exclusion criteria:

  • Patient inability to consent or refusal to participate

Find a Physician

Surgical Services
Weill Cornell Medicine Surgery

Visit our Surgery YouTube channel to view our video library.